TMEM9B

TMEM9B is a glycosylated single-span transmembrane protein of the lysosomal and early endosomal membranes that serves as an accessory β-subunit of endosomal CLC chloride/proton antiporters and as a required component of inflammatory and senescence signaling (PMID:18541524). It interacts strongly and specifically with the endosomal transporters ClC-3 and ClC-4, dramatically reducing their activity and imposing slow activation kinetics on ClC-3, while leaving ClC-7 and ClC-1 currents largely unaffected (PMID:39202776). Cryo-EM structures show that TMEM9B (with its paralog TMEM9) inhibits ClC-3 by sealing the cytosolic entrance to the Cl⁻ ion pathway, an interaction stabilized by PtdIns(3,5)P2 that is required for proper regulation of transporter activity (PMID:40670814). In parallel, TMEM9B is required for TNF-, IL-1β-, and TLR-ligand-induced proinflammatory cytokine production but not for TNF- or Fas-induced apoptosis, acting downstream of RIP1 and upstream of the TAK1 complex to engage both the NF-κB and MAPK branches of these pathways (PMID:18541524). It additionally functions as a downstream effector of the p53-p21 and p16-pRB tumor suppressor pathways, where its silencing bypasses cellular senescence (PMID:21740549).

1. 2008 Medium

   Established that an uncharacterized lysosomal/endosomal transmembrane protein is selectively required for innate inflammatory cytokine output rather than cell death, defining its first cellular role.

   Evidence siRNA knockdown with cytokine assays and subcellular fractionation/localization

   PMID:18541524

   Open questions at the time

   • Molecular partner mediating cytokine signaling not identified
   • single lab, knockdown-based phenotype only
   • mechanism connecting endosomal localization to signaling unclear
2. 2008 Medium

   Placed TMEM9B within the TNF signaling hierarchy by epistasis, showing it acts downstream of RIP1 and upstream of the TAK1 complex to drive both NF-κB and MAPK branches.

   Evidence siRNA epistasis combined with kinase activity assays and pathway-component overexpression

   PMID:18541524

   Open questions at the time

   • No direct biochemical interaction with RIP1 or TAK1 demonstrated
   • how a membrane protein couples to cytosolic kinase complex unresolved
3. 2011 Medium

   Extended TMEM9B function to tumor-suppressor biology, identifying it as a required effector downstream of p53-p21 and p16-pRB whose loss bypasses senescence.

   Evidence RNAi screen with lentiviral shRNA validation and senescence bypass assay in conditionally immortalized fibroblasts

   PMID:21740549

   Open questions at the time

   • Single-method validation in one cell system
   • mechanistic link between TMEM9B and senescence effectors undefined
   • relation to inflammatory role not addressed
4. 2024 High

   Defined a biochemical activity for TMEM9B by showing direct, specific interaction with endosomal CLC transporters and functional inhibition of ClC-3/ClC-4.

   Evidence Xenopus oocyte and HEK cell electrophysiology with FLIM-FRET direct-interaction imaging and ClC-1/ClC-7 specificity controls

   PMID:39202776

   Open questions at the time

   • Structural basis of inhibition not yet resolved
   • physiological consequence of CLC regulation in cells not tested
   • relationship to inflammatory/senescence roles unknown
5. 2025 High

   Provided the structural mechanism of TMEM9B as a CLC accessory β-subunit, showing it seals the cytosolic Cl⁻ pathway of ClC-3 in a PtdIns(3,5)P2-stabilized manner.

   Evidence Cryo-EM structure determination with biochemical reconstitution and lipid-binding assays

   PMID:40670814

   Open questions at the time

   • In vivo physiological role of the TMEM9B–CLC complex not established
   • connection between transporter regulation and signaling functions not bridged

• Whether TMEM9B's CLC-regulatory activity mechanistically underlies its roles in inflammatory signaling and senescence remains unresolved.
• No experiment links CLC antiporter modulation to TAK1/NF-κB-MAPK signaling
• no link between CLC regulation and p53/p16 senescence pathways
• in vivo loss-of-function phenotype not characterized